CAUTIONARY STATEMENT

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding IFF’s expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management and statements containing the words such as “anticipate,” “approximate,” “believe,” “plan,” “estimate,” “expect,” “project,” “could,” “should,” “will,” “intend,” “may” and other similar expressions, are forward-looking statements. Statements in this presentation concerning IFF’s outlook for the second quarter and full year 2020 and beyond and future economic performance, the impact of COVID-19 on its business, anticipated profitability, revenues, expenses or other financial items, the expected impact of the Frutarom integration, including anticipated synergies and cost savings, the expected timetable for completing the proposed transaction with N&B, the benefits and synergies of the proposed transaction with N&B, future opportunities for the combined company and products and any other statements regarding IFF’s and N&B’s future operations, together with other statements that are not historical facts, are forward-looking statements that are estimates reflecting management’s best judgment based upon currently available information.

Factors that could cause IFF’s actual results to differ materially include, but are not limited to: (1) the effect of economic conditions in the industries and markets in which IFF operates in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand, the impact of weather conditions, natural disasters, public health issues, epidemics and pandemics, including the novel coronavirus (COVID-19), or the fear of such events, and the financial condition of IFF’s customers and suppliers; (2) the risks to the Company’s business from the COVID-19 pandemic, including operational risks, supply chain risks, and customer related-risks; (3) risks related to the integration of the Frutarom business, including whether we will realize the benefits anticipated from the acquisition in the expected time frame; (4) unanticipated costs, liabilities, charges or expenses resulting from the Frutarom acquisition, (5) the impact of the outcome of legal claims, regulatory investigations and litigation, (6) the increase in the Company’s leverage resulting from the additional debt incurred to pay a portion of the consideration for the combined company and its impact on the Company’s liquidity and ability to return capital to its shareholders, (7) the Company’s ability to successfully market to its expanded and decentralized Taste and Frutarom customer base, (8) the Company’s ability to effectively compete in its market and develop and introduce new products that meet customers’ needs, (9) the Company’s ability to successfully develop innovative and cost-effective products that allow customers to achieve their own profitability expectations, (10) the impact of the disruption in the Company’s manufacturing operations, (11) the impact of a disruption in the Company’s supply chain, including the inability to obtain ingredients and raw materials from third parties, (12) volatility and increases in the price of raw materials, energy and transportation, (13) the Company’s ability to comply with, and the costs associated with compliance with, regulatory requirements and industry standards, including regarding product safety, quality, efficacy and environmental impact, (14) the impact of any failure or interruption of the Company’s key information technology systems or a breach of information security, (15) the Company’s ability to react in a timely and cost-effective manner to changes in consumer preferences and demands, (16) the Company’s ability to establish and manage collaborations, joint ventures or partnerships that lead to development or commercialization of products, (17) the Company’s ability to benefit from its investments and expansion in emerging markets; (18) the impact of currency fluctuations or devaluations in the principal foreign markets in which it operates; (19) economic, regulatory and political risks associated with the Company’s international operations, (20) the impact of global economic uncertainty on demand for consumer products, (21) the inability to retain key personnel; (22) the Company’s ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws, (23) the Company’s ability to realize the benefits of its cost and productivity initiatives, (24) the Company’s ability to successfully manage its working capital and inventory balances, (25) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, including the U.S. Foreign Corrupt Practices Act, (26) the Company’s ability to protect its intellectual property rights, (27) the impact of the outcome of legal claims, regulatory investigations and litigation, (28) changes in market conditions or governmental regulations relating to our pension and postretirement obligations, (29) the impact of future impairment of our tangible or intangible long-lived assets, (30) the impact of changes in federal, state, local and international tax legislation or policies, including the Tax Cuts and Jobs Act, with respect to transfer pricing and state aid, and adverse results of tax audits, assessments, or disputes, (31) the effect of potential government regulation on certain product development initiatives, and restrictions or costs that may be imposed on the Company or its operations as a result, and (32) the impact of the United Kingdom’s expected departure from the European Union. New risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risks on the Company’s business. Accordingly, the Company undertakes no obligation to publicly revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

In addition to the factors set forth above, other factors that may affect IFF’s plans, results or stock price are set forth in IFF’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Many of these factors are beyond IFF’s control and IFF cautions investors that any forward-looking statements made by IFF are not guarantees of future performance. IFF disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.
Use of Non-GAAP Financial Measures

We provide in this presentation non-GAAP financial measures, including: (i) currency neutral sales; (ii) adjusted operating profit ex amortization; (iii) currency neutral adjusted operating profit ex amortization; (iv) adjusted operating profit margin ex amortization; (v) adjusted EPS ex amortization; (vi) currency neutral adjusted EPS ex amortization; (vii) free cash flow; (viii) legacy standalone Frutarom sales and (ix) net debt to adjusted EBITDA. Our non-GAAP financial measures are defined below. A reconciliation of these non-GAAP financial measures to their respective GAAP measures is available on our website.

Currency Neutral metrics eliminate the effects that result from translating international currency to U.S. dollars. We calculate currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.

Adjusted operating profit/profit margin ex amortization excludes the impact of non-operational items including operational improvement initiatives, integration related costs, restructuring and other charges, net, Frutarom acquisition related costs, compliance review and defense costs, N&B transaction related costs and non-cash items, including gains/losses on sale of assets and the amortization of acquisition related intangible assets.

Adjusted EPS ex Amortization excludes the impact of non-operational items including operational improvement initiatives, integration related costs, restructuring and other charges net, compliance review and defense costs, N&B transaction related costs, non-cash items including gains on sale of assets, redemption value adjustment to EPS and the amortization of acquisition related intangible assets.

Free Cash Flow is operating cash flow (i.e. cash flow from operations) less capital expenditures.

Net Debt to Adjusted EBITDA is the leverage ratio used in our credit agreement and defined as Net Debt (which is long-term debt less cash and cash equivalents) divided by Adjusted EBITDA. However, as Adjusted EBITDA for these purposes were calculated in accordance with the provisions of the credit agreement, it may differ from the calculation used for other purposes.

These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.

CAUTIONARY STATEMENT

We provide in this presentation non-GAAP financial measures, including: (i) currency neutral sales; (ii) adjusted operating profit ex amortization; (iii) currency neutral adjusted operating profit ex amortization; (iv) adjusted operating profit margin ex amortization; (v) adjusted EPS ex amortization; (vi) currency neutral adjusted EPS ex amortization; (vii) free cash flow; (viii) legacy standalone Frutarom sales and (ix) net debt to adjusted EBITDA. Our non-GAAP financial measures are defined below. A reconciliation of these non-GAAP financial measures to their respective GAAP measures is available on our website.

Currency Neutral metrics eliminate the effects that result from translating international currency to U.S. dollars. We calculate currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.

Adjusted operating profit/profit margin ex amortization excludes the impact of non-operational items including operational improvement initiatives, integration related costs, restructuring and other charges, net, Frutarom acquisition related costs, compliance review and defense costs, N&B transaction related costs and non-cash items, including gains/losses on sale of assets and the amortization of acquisition related intangible assets.

Adjusted EPS ex Amortization excludes the impact of non-operational items including operational improvement initiatives, integration related costs, restructuring and other charges net, compliance review and defense costs, N&B transaction related costs, non-cash items including gains on sale of assets, redemption value adjustment to EPS and the amortization of acquisition related intangible assets.

Free Cash Flow is operating cash flow (i.e. cash flow from operations) less capital expenditures.

Net Debt to Adjusted EBITDA is the leverage ratio used in our credit agreement and defined as Net Debt (which is long-term debt less cash and cash equivalents) divided by Adjusted EBITDA. However, as Adjusted EBITDA for these purposes were calculated in accordance with the provisions of the credit agreement, it may differ from the calculation used for other purposes.

These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.
CONFERENCE CALL PARTICIPANTS

Andreas Fibig
Chairman & CEO

Rustom Jilla
EVP & CFO
AGENDA

1. Executive Highlights
2. COVID-19 Situation
3. Financial Review
4. IFF & Dupont N&B Combination
5. Q&A
EXECUTIVE HIGHLIGHTS
Q1 2020 key accomplishments

• Strong start to the year, with mid-single digit sales & double-digit adjusted EPS ex amortization growth – both on currency neutral basis

• Realized solid Frutarom acquisition-related revenue & cost synergies

• Advanced Nutrition & Biosciences integration planning, culminating with new purpose, vision, operating model & leadership appointments

• Incredibly proud of all IFF colleagues, who delivered for our customers & supported our communities globally through COVID-19 pandemic

• Global conditions remain volatile & unpredictable; Taking action to ensure we're well-positioned to successfully manage through near-term challenges & emerge as a stronger company
Q1 2020 FINANCIAL SUMMARY
Delivered strong improvements across key financial metrics

- Currency neutral sales grew 6% with broad-based growth in both Taste & Scent
- Currency neutral adjusted operating margin excluding amortization +60 bps to 20.1%
- Achieved significant 13% year-over-year increase in currency neutral adjusted EPS excluding amortization

$1.3B
SALES

$271M
ADJ. OPERATING PROFIT EX AMORT*

$1.62
ADJ. EPS EX AMORT*

* Non-GAAP metric; please see Non-GAAP disclosures at ir.iff.com
COVID-19: PORTFOLIO ANALYSIS
Diverse & defensive business supporting essential consumer products industries

**CHARACTERISTICS**

- **Global**: selling products in ~200 countries globally
- **Diverse**: broad-based exposure across regions, categories & customers
- **Defensive**: ingredients & compounds a key component of consumer staples products
- **Essential**: vast portfolio deemed as essential for food, beverages, home & personal care products
- **Discretionary/Away From Home**: Fine Fragrance, Cosmetic Actives & Food Service (~15% of sales) temporarily impact by COVID-19

**PORTFOLIO COMPOSITION**

- ~15% of sales
  - Fine Fragrance, Cosmetic Actives / Food Service
- ~85% of sales
  - Rest of portfolio

2019 Consolidated Sales

~$5B
COVID-19: IMPACT ASSESSMENT
Team is successfully navigating a volatile & unpredictable environment

1. **Procurement**
   - Proactively addressing raw material challenges
   - Cost modestly higher due to supply constraint

2. **Logistics**
   - Lead times increased given new policies & regulations
   - Successfully managing logistics with minimal incremental costs

3. **Manufacturing**
   - Enacting business continuity plan for minimal disruptions
   - Expenses increasing to support higher demand & new protocols

4. **Creative & Application**
   - Most Creative Centers open; Engaging remotely as needed
   - Project pipeline remains solid across entire portfolio
COVID-19: ACTIONS
Taking steps to ensure continued success

1. Disciplined Cost Management: Limiting non-essential expenses & targeting incremental productivity initiatives to protect margin profile

2. Capital Expenditure Reduction: Prioritizing projects with shortest payback periods & delaying those that do not generate immediate returns

3. Net Working Capital Optimization: Assessing opportunities to selectively reduce inventory & drive greater emphasis on collections

4. Capital Structure Optimization: Strong cash position in Q1 2020, with $1B of untapped credit revolver available
COVID-19: SOCIAL RESPONSIBILITY
Supporting our people, customers & communities around the world

COMMUNITY OUTREACH

- Local teams collectively produced >65 tons of hand sanitizer to date to be distributed to first responders
- Partnered to develop “smell strips” that help identify an early sign of COVID-19 via sense of smell
- Implemented COVID-19 Fund & Gift Matching Program for either employee or next of kin hardship
- Increased employee health & safety via work from home for non-essentials, embracing social distancing, restricting travel, enhancing cleaning procedures and modifying procedures to protect essential employees to serve customers
Q1 2020 FINANCIAL PERFORMANCE
Achieved robust leverage from sales to EPS on a currency neutral basis

**CURRENCY NEUTRAL SALES GROWTH***

<table>
<thead>
<tr>
<th></th>
<th>Sales</th>
<th>Adjusted Operating Profit ex Amort</th>
<th>Adjusted EPS ex Amort</th>
</tr>
</thead>
<tbody>
<tr>
<td>6%</td>
<td>9%</td>
<td>13%</td>
<td></td>
</tr>
</tbody>
</table>

**COMMENTARY**

- Broad-based sales growth in Scent & Taste and across all regions
- Margin expansion and strong increase in profit driven by volume & productivity, that more than offset modest COVID-19 impact
- Currency adjusted EPS ex amort up double-digits with robust profit growth boosted by lower interest and taxes
- Devaluation of emerging market currencies vs the USD adversely impacted our reported adjusted EPS ex amort

12 * Currency Neutral Sales, Adjusted Operating Profit Margin Ex Amortization & Currency Neutral Adjusted EPS Ex Amortization are Non-GAAP metrics, please see our GAAP to Non-GAAP Reconciliation at ir.iff.com
SCENT RESULTS
Q1 2020 performance review

CURRENCY NEUTRAL SALES GROWTH*

**Q1 2020**: +7%

- Growth in all regions and nearly all categories
- Double-digit increase in Consumer Fragrance led by robust growth in Fabric, Home & Hair Care
- Fragrance Ingredients increased high-single digits
- Fine Fragrance declined due to Covid-19 which caused a sharp deceleration late in the quarter

SEGMENT PROFIT

- Currency neutral profit growth of 19% driven by sales volumes & operating expenses

*Non-GAAP metric; please see Non-GAAP disclosures at ir.iff.com*
TASTE RESULTS
Q1 2020 performance review

**CURRENCY NEUTRAL SALES GROWTH**

**Q1 2020:** +5%

- Achieved increases in all regions, with mid to high-single digit growth in LATAM, Greater Asia & EAME
- Growth was primarily driven by mid-teens growth in Savory Solutions while Flavors increased low single digits
- If we had measured Frutarom as a standalone, sales would have grown by ~4%

**SEGMENT PROFIT**

- Currency neutral profit growth of 6% led by volume benefits & integration-related synergies
- Includes approximately $44M of amortization of intangible assets

*Non-GAAP metric; please see Non-GAAP disclosures at ir.iff.com

** Includes approximately $44M of amortization of intangible assets
CASH FLOW DYNAMICS
Q1 2020 performance review

**Q1 2020 CASH FLOW**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$127</td>
<td>$81</td>
<td>$(166)</td>
<td>$(25)</td>
<td>$17</td>
<td>$(48)</td>
<td>$(31)</td>
</tr>
</tbody>
</table>

**COMMENTARY**

**Operating Cash Flow**
- Impacted by higher working capital as a result of strong sales & 2019 calendar shift
- Cash conversion cycle in Q1 2020 was consistent with 2019's first quarter

**Capital Expenditures**
- Capex was ~3.6% of sales vs. 4.5% in prior year

**Free Cash Flow**
- Q1 is seasonably the lowest quarter of the year

**Usage of Cash**
- $94M spent on M&A/Dividends vs. $112M in Q1 2019

---

15 * Core Working Capital includes Accounts Receivables, Inventories and Accounts Payables
** Free cash flow defined as operating cash flow less capex
COVID-19: BUSINESS MANAGEMENT LEVERS
Targeting reductions in operational & capital expenses

COST STRUCTURE

<table>
<thead>
<tr>
<th>Cost Category</th>
<th>% of 2019 Net Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating Profit</td>
<td>~15%</td>
</tr>
<tr>
<td>Variable Costs</td>
<td>~55%</td>
</tr>
<tr>
<td>Fix Costs</td>
<td>~30%</td>
</tr>
</tbody>
</table>

WORKING CAPITAL

<table>
<thead>
<tr>
<th>Working Capital Category</th>
<th>% of 2019 Net Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receivables</td>
<td>17%</td>
</tr>
<tr>
<td>Inventory</td>
<td>22%</td>
</tr>
<tr>
<td>Payables</td>
<td>(10)%</td>
</tr>
</tbody>
</table>

CAPEX

<table>
<thead>
<tr>
<th>Capital Expenditure</th>
<th>% of 2019 Net Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expansion</td>
<td>~1.5%</td>
</tr>
<tr>
<td>Maintenance</td>
<td>~3.5%</td>
</tr>
</tbody>
</table>
COVID-19: INSIGHT INTO DEBT PROFILE
Phased debt maturity schedule, with strong & ample liquidity

<table>
<thead>
<tr>
<th>DEBT MATURITY SCHEDULE (USD)</th>
<th>COMMENTARY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Committed to maintaining investment grade rating</td>
</tr>
<tr>
<td></td>
<td>• T12M Net Debt to EBITDA in Q1 2020 was 3.3x</td>
</tr>
<tr>
<td></td>
<td>• Debt covenants:</td>
</tr>
<tr>
<td></td>
<td>- 4.0x Net Debt to EBITDA as of March 31, 2020</td>
</tr>
<tr>
<td></td>
<td>- 3.5x Net Debt to EBITDA as of March 31, 2021</td>
</tr>
<tr>
<td></td>
<td>• Cash position strong at $433M, with $1B of untapped credit revolver available</td>
</tr>
</tbody>
</table>

• Committed to maintaining investment grade rating

• T12M Net Debt to EBITDA in Q1 2020 was 3.3x

• Debt covenants:
  - 4.0x Net Debt to EBITDA as of March 31, 2020
  - 3.5x Net Debt to EBITDA as of March 31, 2021

• Cash position strong at $433M, with $1B of untapped credit revolver available
**INSIGHT INTO Q2 2020 DYNAMICS**
COVID-19 presenting both opportunities & challenges

<table>
<thead>
<tr>
<th>CONTINUED STRENGTH</th>
<th>SUPPLY CHALLENGE</th>
<th>MARKET PRESSURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taste Ex Food Service</td>
<td>Consumer Fragrances</td>
<td>Fragrance Ingredients</td>
</tr>
<tr>
<td>Food Service</td>
<td>Fine Fragrances / Cosmetic Actives</td>
<td></td>
</tr>
</tbody>
</table>

---

*Image icons representing each category are included.*
LOOKING AHEAD
Global conditions remain volatile & unpredictable

• Fortunate that majority of portfolio is essential for food, beverage, home & personal care products, with positive impact from COVID-19

• Remainder of our portfolio (Fine Fragrances, Cosmetic Actives, Fragrance Ingredients & Food Service) negatively impacted by COVID-19

• April sales challenged on a currency neutral basis

• Expect near-term margin headwind from an unfavorable sales mix and additional COVID-19 related costs

• Will provide an update as we gain more visibility in Q2 2020

• FY 2020 financial guidance has been withdrawn
IFF AND DUPONT N&B COMBINATION
Creating a new global leader for innovative integrated solutions

**BROADENS CATEGORY EXPOSURE**
- Expands breadth of capabilities
- #1 or #2 position across high-value ingredients

**EXPANDS R&D CAPABILITIES & EXPERTISE**
- Best-in-class R&D and innovation capabilities
- Strongest industry pipeline with exceptional talent

**DIFFERENTIATED INTEGRATED SOLUTIONS**
- Stronger & broadest differentiated product offerings
- Improve speed-to-market & simplification for customers
INTEGRATION PLANNING
Strong progress in pre-integration phase; On-track with execution timeline

<table>
<thead>
<tr>
<th>Q4 2019</th>
<th>FIRST HALF 2020</th>
<th>SECOND HALF 2020</th>
<th>Q1 2021</th>
<th>POST CLOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agreement Signed</td>
<td>Integration Management Office Formation</td>
<td>Cleared U.S. Regulatory Process</td>
<td>Initial Registration Statement</td>
<td>Purpose, Vision, Operating Model &amp; Leadership</td>
</tr>
</tbody>
</table>

Key Activities
- ✓ Completed strategic assessment of the future combined company portfolio
- ✓ Joint cross functional integration program in place & operational
- ✓ Cleared U.S. antitrust process & filed for Europe and China approvals
- ✓ Created ideation framework to identify, assess & prioritize synergy opportunities
- ✓ Announced Purpose & Vision of future combined company
- ✓ Defined operating model & made executive leadership selections

Integration Activities On-Track for Q1 2021 Close
It’s not just that we’re talented scientists and creators, but that we’re passionate about using those talents to generate results for our customers, and for the world.

We’re shaping the future of the industry, for the better.
We’re more than a supplier. Yes, we supply the ingredients, compounds, and solutions that our customers require, but we are also united in understanding and meeting the challenges of today as well as tomorrow.

We create solutions based on what’s essential for our customers.

**OUR VISION:**

BE THE PARTNER FOR ESSENTIAL SOLUTIONS

It’s our strategy for future success.

Unmatched innovation and leading-edge insight mean we’re already anticipating what will be essential to tomorrow’s consumers.
STRUCTURING FOR ACCELERATED GROWTH
Establishment of four divisions focused on end-market demand

**TASTE, FOOD & BEVERAGE**
- Flavors
- Savory Solutions
- Inclusions
- Functional Solutions
- Protein Solutions
- Emulsifiers & Sweeteners
- Food Protection
- Colors

~$6.1 Billion*

**SCENT**
- Scent
- Ingredients
- Cosmetic Actives

~$2.0 Billion*

**HEALTH & BIOSCIENCES**
- Probiotics, Infant Nutrition, HMO** & Fibers
- Food Enzymes
- Cultures
- Home & Personal Care
- Animal Health & Nutrition
- Microbial Control
- Biorefineries
- Health Ingredients

~$2.3 Billion*

** PHARMA SOLUTIONS **
- Pharma Excipients
- Global Specialty Solutions
- Industrial

~$0.8 Billion*

---

* Based on 2019 sales on a combined pro forma basis

** Human Oligosaccharides
## Supporting Business Objectives

Global centralized functions, focused on best-in-class expertise

### Integrated Solutions
- Creating new opportunities in total product solutions

### Commercial Excellence
- Collaborating for best practices & standardization

### Research & Development
- Defining what’s next via global innovation & sustainability

### Global Operations
- Driving best-in-class operations, safely and responsibly

### Finance
- Preserving financial strength & ensuring delivery of aspiration

### Taste, Food & Beverage

### Scent

### Health & Biosciences

### Pharma Solutions

### Human Resources
- Looking after our people, embracing diversity & inclusion

### IR & Comms
- Telling the story of IFF to all stakeholders

### Information Technology
- Bringing our network together & digitizing our future

### Legal
- Keeping us competitive, compliant & protected

### Strategy*
- Planning what’s ahead & shaping how we get there

---

* Responsible for Financial, Planning & Analysis, dual reporting to CFO
## EXECUTIVE COMMITTEE
Highly qualified & diverse leaders with deep knowledge and expertise

<table>
<thead>
<tr>
<th>CHAIRMAN &amp; CEO</th>
<th>PHARMA SOLUTIONS</th>
<th>SCENT</th>
<th>HEALTH &amp; BIOSCIENCES</th>
<th>TASTE, FOOD &amp; BEVERAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andreas Fibig</td>
<td>Angela Strzelecki</td>
<td>Nicolas Mirzayantz</td>
<td>Simon Herriott</td>
<td>Matthias Haeni</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LEGAL</th>
<th>OPERATIONS</th>
<th>RESEARCH &amp; DEVELOPMENT</th>
<th>FINANCE</th>
<th>INTEGRATED SOLUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Johnson</td>
<td>Francisco Fortanet</td>
<td>Angela Naef</td>
<td>Rustom Jilla</td>
<td>Gregory Yep</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INFORMATION TECHNOLOGY</th>
<th>IR &amp; COMMUNICATIONS</th>
<th>COMMERCIAL EXCELLENCE</th>
<th>HUMAN RESOURCES</th>
<th>STRATEGY*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vic Verma</td>
<td>Michael DeVeau</td>
<td>Greg Soutendijk</td>
<td>Susana Suarez</td>
<td>Etienne Laurent</td>
</tr>
</tbody>
</table>

* Responsible for Financial, Planning & Analysis, dual reporting to CFO
BOARD OF DIRECTORS DESIGNEES

Beginning to assemble a world-class board

Ed Breen

Breen is Executive Chairman and CEO of DuPont de Nemours, Inc. ("DuPont"), formerly DowDuPont Inc. ("DowDuPont"), and has served as CEO and/or Executive Chair of DuPont since the merger of The Dow Chemical Company and E. I. du Pont de Nemours and Company ("EID") on August 31, 2017, and of EID from October 2015 until DowDuPont’s spin off of Corteva, Inc. on June 1, 2019.

Prior to DuPont, Breen served as chairman, from July 2002 to March 2016, and CEO from July 2002 to September 2012, of Tyco International plc ("Tyco").

Breen currently serves as a director of Comcast Corporation and a member of the advisory board of New Mountain Capital LLC, a private equity firm.

Matthias Heinzel

Dr. Heinzel is President, DuPont Nutrition & Biosciences and has led the segment through a series of acquisitions and integrations since 2015.

Heinzel joined DuPont in 2003 and held leadership positions in its Electronics & Communications business at the company.

Prior to DuPont, Heinzel held leadership roles in the telecommunications industry and worked with a leading international management consultancy.

He holds a master degree in electrical engineering and business administration (Dipl.-Wirtschaftsing.) and a Ph.D. in business administration.

Carol Anthony (John) Davidson

Davidson is the former senior vice president, controller and chief accounting officer of Tyco International. He retired in 2012 following an eight year tenure at the company.

Davidson served as vice president, audit, risk and compliance for Dell Inc and earlier spent 16 years at Eastman Kodak where he led the company’s internal audit function.

Davidson has served on numerous boards, including the board of governors of the Financial Industry Regulatory Authority. Currently, he is the lead independent director for Legg Mason and a Board member of TE Connectivity.
INTEGRATION PLANNING
Strong progress in pre-integration phase; On-track with execution timeline

Key Activities
✓ Completed strategic assessment of the future combined company portfolio
✓ Cleared U.S. antitrust process & filed for Europe and China approvals
✓ Announced Purpose & Vision of future combined company
✓ Joint cross functional integration program in place & operational
✓ Created ideation framework to identify, assess & prioritize synergy opportunities
✓ Defined operating model & made executive leadership selections

Integration Activities On-Track for Q1 2021 Close
Strong start to the year, with strong top and bottom-line results

Realized Frutarom acquisition-related revenue & cost synergies & made significant advancements in N&B integration planning

Unveiled future combined company purpose, vision, operating model & leadership team to ensure day 1 readiness

Incredibly proud of all ofIFF for what we achieved during these challenging times – supporting our business and community

Well-positioned to successfully navigate uncertain world & emerge as a stronger company
## 2019 Financials for New Reporting Segments**

<table>
<thead>
<tr>
<th></th>
<th>Q1 2019</th>
<th>Q2 2019</th>
<th>Q3 2019</th>
<th>Q4 2019</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taste Sales</td>
<td>805</td>
<td>811</td>
<td>782</td>
<td>802</td>
<td>3201</td>
</tr>
<tr>
<td>Taste Segment Profit</td>
<td>131</td>
<td>131</td>
<td>121</td>
<td>99</td>
<td>482</td>
</tr>
<tr>
<td>as % of sales</td>
<td>16.3%</td>
<td>16.1%</td>
<td>15.5%</td>
<td>12.3%</td>
<td>15.1%</td>
</tr>
<tr>
<td>Scent Sales</td>
<td>493</td>
<td>480</td>
<td>485</td>
<td>482</td>
<td>1940</td>
</tr>
<tr>
<td>Scent Segment Profit</td>
<td>90</td>
<td>94</td>
<td>88</td>
<td>77</td>
<td>349</td>
</tr>
<tr>
<td>as % of sales</td>
<td>18.3%</td>
<td>19.6%</td>
<td>18.1%</td>
<td>16.1%</td>
<td>18.0%</td>
</tr>
<tr>
<td>Corporate Expenses:</td>
<td>(17)</td>
<td>(11)</td>
<td>(8)</td>
<td>(3)</td>
<td>(39)</td>
</tr>
<tr>
<td>Consolidated Sales</td>
<td>1297</td>
<td>1292</td>
<td>1267</td>
<td>1284</td>
<td>5140</td>
</tr>
<tr>
<td>Adjusted Consolidated Operating Profit*</td>
<td>205</td>
<td>214</td>
<td>201</td>
<td>174</td>
<td>793</td>
</tr>
<tr>
<td>as % of sales</td>
<td>15.8%</td>
<td>16.6%</td>
<td>15.9%</td>
<td>13.5%</td>
<td>15.4%</td>
</tr>
<tr>
<td>Amortization</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>49</td>
<td>193</td>
</tr>
<tr>
<td>Adjusted Consolidated Operating Profit Ex Amort*</td>
<td>252</td>
<td>262</td>
<td>249</td>
<td>223</td>
<td>986</td>
</tr>
<tr>
<td>as % of sales</td>
<td>19.4%</td>
<td>20.3%</td>
<td>19.7%</td>
<td>17.3%</td>
<td>19.2%</td>
</tr>
</tbody>
</table>

* Adjusted Operating Profit & Adjusted Operating Profit Ex Amortization are Non-GAAP metrics, please see our GAAP to Non-GAAP Reconciliations for the applicable periods at ir.iff.com.

** This appendix provides unaudited summary financial information and other data according to the new reporting segments for the previously reported year ended December 31, 2019, and the previously reported quarters in the year ended December 31, 2019. This information in no way revises or restates the Company's previously reported consolidated financial statements for any period. It does not change the Company's previously reported total assets, liabilities or shareholders' equity or its reported net income or earnings per share, nor does it reflect any subsequent information or events, other than as required to reflect the change in reporting segments as described above. This information should be read in conjunction with our previously filed reports. The Company's procedures for the recast of this financial information are not yet complete and, as a result, the recast financial information presented above is preliminary in nature. Adjustments to the preliminary recast financial information above may be identified as a result of the completion of the Company's recast procedures between now and the time that the full recast of the Company's financial information for the year ended December 31, 2019 and any previously reported fiscal quarter is released. Amounts may not foot due to rounding.